The use of metabolising systems for in vitro testing of endocrine disruptors

Miriam Jacobs*, W. Janssens, U. Bernauer, E. Brandon, S. Coecke, R. Combes, P. Edwards, A. Freidig, A. Freyberger, R. Kolanczyk, C. Mc Ardie, O. Mekenyan, P. Schmieder, T. Schrader, M. Takeyoshi, B. van der Burg

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

35 Citations (Scopus)


Legislation and prospective legislative proposals in for instance the USA, Europe, and Japan require, or may require that chemicals are tested for their ability to disrupt the hormonal systems of mammals. Chemicals found to test positive are considered to be endocrine active substances (EAS) and may be putative endocrine disruptors (EDs). To date, there is still little or no experience with incorporating metabolic and toxicokinetic aspects into in vitro tests for EAS. This is a situation in sharp contrast to genotoxicity testing, where in vitro tests are routinely conducted with and without metabolic capacity. Originally prepared for the Organisation of Economic Cooperation and Development (OECD), this detailed review paper reviews why in vitro assays for EAS should incorporate mammalian systems of metabolism and metabolic enzyme systems, and indicates how this could be done. The background to ED testing, the available test methods, and the role of mammalian metabolism in the activation and the inactivation of both endogenous and exogenous steroids are described. The available types of systems are compared, and the potential problems in incorporating systems in in vitro tests for EAS, and how these might be overcome, are discussed. Lastly, some recommendations for future activities are made.

Original languageEnglish
Pages (from-to)796-826
Number of pages31
JournalCurrent Drug Metabolism
Issue number8
Publication statusPublished - 2008


  • Androgenicity
  • Cytochrome P450
  • Endocrine active substances
  • Endocrine disruption
  • Estrogenicity
  • Metabolism


Dive into the research topics of 'The use of metabolising systems for in vitro testing of endocrine disruptors'. Together they form a unique fingerprint.

Cite this